

UBE2O Antibody (C-Terminus)
Goat Polyclonal Antibody
Catalog # ALS14222**Specification**

UBE2O Antibody (C-Terminus) - Product Information

Application	IHC
Primary Accession	O9C0C9
Reactivity	Human, Monkey
Host	Goat
Clonality	Polyclonal
Calculated MW	141kDa KDa

UBE2O Antibody (C-Terminus) - Additional Information**Gene ID** 63893**Other Names**

E2/E3 hybrid ubiquitin-protein ligase UBE2O, 6.3.2.-, 6.3.2.19, Ubiquitin carrier protein O, Ubiquitin-conjugating enzyme E2 O, Ubiquitin-conjugating enzyme E2 of 230 kDa, Ubiquitin-conjugating enzyme E2-230K, Ubiquitin-protein ligase O, UBE2O, KIAA1734

Target/Specificity

Human UBE2O.

Reconstitution & Storage

Store at -20°C. Minimize freezing and thawing.

Precautions

UBE2O Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

UBE2O Antibody (C-Terminus) - Protein Information**Name** UBE2O**Synonyms** KIAA1734**Function**

E2/E3 hybrid ubiquitin-protein ligase that displays both E2 and E3 ligase activities and mediates monoubiquitination of target proteins (PubMed:23455153, PubMed:24703950). Negatively regulates TRAF6-mediated NF-kappa-B activation independently of its E2 activity (PubMed:23381138). Acts as a positive regulator of BMP7 signaling by mediating monoubiquitination of SMAD6, thereby regulating adipogenesis (PubMed:23455153). Mediates monoubiquitination at different sites of the nuclear

localization signal (NLS) of BAP1, leading to cytoplasmic retention of BAP1. Also able to monoubiquitinate the NLS of other chromatin-associated proteins, such as INO80 and CXXC1, affecting their subcellular location (PubMed:24703950). Acts as a regulator of retrograde transport by assisting the TRIM27:MAGEL2 E3 ubiquitin ligase complex to mediate 'Lys-63'-linked ubiquitination of WASHC1, leading to promote endosomal F-actin assembly (PubMed:23452853).

Cellular Location

Cytoplasm. Nucleus. Note=Mainly localizes to the cytoplasm

Tissue Location

Predominantly expressed in skeletal muscle and heart.


Volume

50 µl

UBE2O Antibody (C-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

UBE2O Antibody (C-Terminus) - Images

Anti-UBE2O antibody IHC of human skeletal muscle.

UBE2O Antibody (C-Terminus) - Background

E2/E3 hybrid ubiquitin-protein ligase that displays both E2 and E3 ligase activities and mediates monoubiquitination of target proteins (PubMed:23455153, PubMed:24703950). Negatively regulates TRAF6-mediated NF-kappa-B activation independently of its E2 activity (PubMed:23381138). Acts as a positive regulator of BMP7 signaling by mediating monoubiquitination of SMAD6, thereby regulating adipogenesis (PubMed:23455153). Mediates monoubiquitination at different sites of the nuclear localization signal (NLS) of BAP1, leading to cytoplasmic retention of BAP1. Also able to

monoubiquitinate the NLS of other chromatin- associated proteins, such as INO80 and CXXC1, affecting their subcellular location (PubMed:24703950). Acts as a regulator of retrograde transport by assisting the TRIM27:MAGEL2 E3 ubiquitin ligase complex to mediate 'Lys-63'-linked ubiquitination of WASH1, leading to promote endosomal F-actin assembly (PubMed:23452853).

UBE2O Antibody (C-Terminus) - References

Nagase T.,et al.DNA Res. 7:347-355(2000).
Zody M.C.,et al.Nature 440:1045-1049(2006).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Ota T.,et al.Nat. Genet. 36:40-45(2004).